Effect of tenascin C on brain tumor initiating cells
Ontology highlight
ABSTRACT:
ORGANISM(S): Homo sapiens
PROVIDER: GSE94640 | GEO | 2017/02/08
SECONDARY ACCESSION(S): PRJNA371648
REPOSITORIES: GEO
Similar Datasets
Project description:We have determined that demeclocycline reduces the growth of brain tumor initiating cells (BTICs). Specifically, we sought to obtain insights into the mechanisms by which demeclocycline directly regulates BTIC growth. Analysis of the array data identified several genes that were altered with demeclocycline treatment that could regulate BTIC growth. The study provides the mechanistic basis for the regulation of BTIC growth with demeclocycline treatment.
2016-05-18 | GSE81515 | GEO
Project description:We have determined that demeclocycline reduces the growth of brain tumor initiating cells (BTICs). Specifically, we sought to obtain insights into the mechanisms by which demeclocycline directly regulates BTIC growth. Analysis of the array data identified several genes that were altered with demeclocycline treatment that could regulate BTIC growth. The study provides the mechanistic basis for the regulation of BTIC growth with demeclocycline treatment. We subjected 3 BTIC lines to microarray analyses to identify genes involved in the regulation of BTIC growth by demeclocycline. Three BTIC lines (BT012, BT025 and BT048) were treated with 10 µM demeclocycline for 6h. One (1) control and 1 treatment (demeclocycline treated) sample was generated from each BTIC line. Thus, a total of 6 RNA samples from 3 BTIC lines were obtained for microarray analysis.
2016-05-18 | E-GEOD-81515 | biostudies-arrayexpress
Project description:Glioblastomas coopt stem cell regulatory pathways to maintain brain tumor initiating cells (BTICs), also known as cancer stem cells. Notch signaling has been a molecular target in BTICs, but Notch antagonists have demonstrated limited efficacy in clinical trials. RBPJ is considered a central transcriptional mediator of Notch activity. Here, we report that pharmacologic Notch inhibitors were less effective than targeting RBPJ in suppressing tumor growth. While Notch inhibitors decreased canonical Notch gene expression, RBPJ regulated a distinct profile of genes critical to BTIC stemness and cell cycle progression. RBPJ was preferentially expressed by BTICs and required for BTIC self-renewal and tumor growth. MYC, a key BTIC regulator, bound the RBPJ promoter and treatment with a BET family bromodomain inhibitor decreased MYC and RBPJ expression. Proteomic studies demonstrated that RBPJ binds CDK9, a component of P-TEFb (positive transcription elongation factor), to target gene promoters, enhancing transcriptional elongation. Collectively, RBPJ links MYC and transcriptional control through CDK9, providing potential nodes of fragility for therapeutic intervention, potentially distinct from Notch.
2016-05-01 | GSE79735 | GEO
Project description:In order to investigate what signalling pathways are turned on by tenascin-C, we generated Mouse Embryonic Fibroblasts (MEFs) deficient for tenascin-C and compared their gene expression profile to MEFs proficient for tenascin-C. TNC-KO MEFs as well as WT MEFs in which tenascin-C was knocked-down (following stable transfection of a short hairpin RNA) were compared to WT MEFs (expressing strong endogenous levels of tenascin-C).
2011-02-22 | E-GEOD-23547 | biostudies-arrayexpress
Project description:We have found that innate immune cells (monocytes/macrophages) are compromised in malignant glioma, and we have determined that vitamin B3 (niacin) reactivates and/or reprograms monocytes/macrophages to inhibit glioma growth, particularly by suppressing the growth of brain tumor initiating cells (BTICs). To this end, we sought to obtain insights into the mechanisms by which niacin regulates monocyte/macrophage activity to alter glioma growth. Analysis of the microarray data identified several genes that were differentially altered in niacin-treated monocytes that could regulate BTIC growth. The study has identified a mechanistic basis for the regulation of glioma growth with niacin treatment.
2017-09-05 | GSE103381 | GEO
Project description:Determination of the mechanism by which microglia regulate growth of brain tumor initiating cells (BTICs) and differentiation. Results identify the factors involved in the regulation and provide mechanistic basis. We subjected brain tumor initiating cells to microarray to determine the genes involved in BTICs growth and differentiation when exposed to microglia conditioned medium (MCM) for 6h. BTICs were grown in MCM or control medium for 6h, and media was removed and then the cells were subjected for RNA extraction and hybridization on Affymatrix microarrays. Three (3) control and four (4) MCM samples were generated. The overall objective was to collect the RNA from the MCM exposed differentiated BTICs.
2013-11-06 | E-GEOD-52127 | biostudies-arrayexpress
Project description:Determination of the mechanism by which microglia regulate growth of brain tumor initiating cells (BTICs) and differentiation. Results identify the factors involved in the regulation and provide mechanistic basis. We subjected brain tumor initiating cells to microarray to determine the genes involved in BTICs growth and differentiation when exposed to microglia conditioned medium (MCM) for 6h.
2013-11-06 | GSE52127 | GEO
Project description:TRAIL cytotoxicity is exploited as anti-cancer therapy since many years, however incomplete knowledge is generating many obstacles. Here, we address whether the highly abundant extracellular matrix molecule tenascin-C (TNC) orchestrating an immune suppressive tumor microenvironment and binding TRAIL impacts TRAIL cytotoxicity. We used an immune competent autologous NT193 breast cancer model with a knockdown (KD) of Tnfsf10 (encoding TRAIL) and observed accelerated tumor growth marked by less apoptosis, more proliferation and less myeloid cell infiltration as seen by flow cytometry. Grafting the same Tnfsf10 KD cells into a TNC knockout host showed repressed tumor growth suggesting that TNC is involved in regulating TRAIL functions.
2024-05-30 | E-MTAB-14089 | biostudies-arrayexpress
Project description:Tenascin-C (TNC), a cancer-associated extracellular matrix glycoprotein, plays a pivotal role in tumor growth. However, the mechanism whereby TNC affects tumor biology remains unclear. We used microarrays to investigate change in global gene expression between tumors in wild-type (WT) mice, which express TNC, and tumors in TNC-knockout (TNKO) mice. We developed a non-TNC-producing mouse mammary tumor cell line (GLMT1). GLMT1 was inoculated in the drosal flank of WT mice and TNKO mice. After 14 days, the tumor were harvested and RNA was extracted. Subsequently, they were processed and hybridized on Affymetrix GeneChip Mouse Genome 430 2.0 Array
2016-02-10 | E-GEOD-77739 | biostudies-arrayexpress
Project description:Transcriptome analysis on ING5-knockdown brain tumor stem cell lines Stem cell-like brain tumor initiating cells (BTICs) cause recurrence of glioblastomas, with BTIC "stemness" affected by epigenetic mechanisms. The ING family of epigenetic regulators (ING1-5) function by targeting histone acetyltransferase (HAT) or histone deacetylase (HDAC) complexes to the H3K4me3 mark to alter histone acetylation and subsequently, gene expression. Here we find that ectopic expression of ING5, the targeting subunit of HBO1, MOZ and MORF HAT complexes increases expression of the Oct4, Olig2 and Nestin stem cell markers, promotes self-renewal, prevents lineage differentiation and increases stem cell pools in BTIC populations. This activity requires the plant homeodomain region of ING5 that interacts specifically with the H3K4me3 mark. ING5 also enhances PI3K/AKT and MEK/ERK activity to sustain self-renewal of BTICs over serial passage of stem cell-like spheres. ING5 exerts these effects by activating transcription of calcium channel and follicle stimulating hormone (FSH) pathway genes. In silico analyses of The Cancer Genome Atlas (TCGA) data suggest that ING5 is a positive regulator of BTIC stemness, whose expression negatively correlates with patient prognosis, especially in the Proneural and Classical subtypes, and in tumors with low SOX2 expression. These data suggest that altering histone acetylation status and signaling pathways induced by ING5 may provide useful clinical strategies to target tumor resistance and recurrence in glioblastoma.
2017-06-24 | GSE100398 | GEO